Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK- 462) in the acute treatment of migraine

Cephalalgia

Volumn 17, Issue 6, 1997, Pages 647-651

  Gijsman, H ^a   Kramer, M S ^b   Sargent, J ^c   Tuchman, M ^d   Matzura Wolfe, D ^b   Polis, A ^b   Teall, J ^e   Block, G ^b   Ferrari, M D ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MERCK RESEARCH LABORATORIES   (United States)

^c MENNINGER CLINIC   (United States)

^d Palm Beach Neurological Group   (United States)

^e Merck Laboratories   (United Kingdom)

Author keywords

5HT(ID) receptor agonist; Migraine; MK 462; Rizatriptan

Indexed keywords

RIZATRIPTAN; SEROTONIN 1 AGONIST; SEROTONIN 1D RECEPTOR;

ADULT; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA; SOMNOLENCE; VERTIGO; XEROSTOMIA;

ACUTE DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIGRAINE DISORDERS; REGRESSION ANALYSIS; SEROTONIN AGONISTS; TRIAZOLES; TRYPTAMINES;

EID: 0030769110     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.1997.1706647.x     Document Type: Article

References (13)

1. Moskowitz MA. Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology 1993;43:516-20
2. Humphrey PP. 5-Hydroxytryptamine and the pathophysiology of migraine. J Neurol 1991;238:538-44
3. Moskowitz MA, MacFarlane R. Neurovascular and molecular mechanisms of migraine headaches. Cerebrovasc Brain Metab Rev 1993;5:159-77
4. Deliganis AV, Peroutka SJ. 5-hydroxytryptamine 1D receptor agonism predicts antimigraine efficacy. Headache 1991;31: 228-31
5. Plosker GL, McTavish D. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1994;47:622-51
6. 1-like receptor agonist. Br J Pharmacol 1989;96:379-87
7. Feniuk W, Humphrey PPA, Perren MJ. The selective carotid arterial vasoconstrictor action of GR 43175 in anesthetized dogs. Br J Pharmacol 1990;99:202-6
8. 1B/1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine. Cephalalgia 1991;11:165-8
9. Peroutka SJ. Developments in 5-hydroxytryptamine receptor pharmacology in migraine. Neurol Clin 1990;8:829-39
10. 1D agonist. Clin Pharmac Ther 1994;55:129
11. Visser WH, Terwindt G, Reines S, Jiang K, Lines C, Ferrari M. Rizatriptan vs. Sumatriptan in the acute treatment of migraine. Arch Neurol 1996;53:1132-7
12. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain. Cephalalgia 1988;8:19-28
13. Hochberg. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800-2